← Back to Search

Naloxone Hydrochloride for Opioid Use Disorder

Phase 1
Waitlist Available
Led By D. Andrew Tompkins, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up k will be calculated from the same series of discounting questions that will be asked once each session at approcimately 30 minutes after study im medication administration.
Awards & highlights

Study Summary

This trial will test how chronic pain is associated with increases in impulsive decision making in OUD, whether impulsive decision making is greater when undergoing opioid withdrawal, and how catastrophizing may modify the association between withdrawal and impulsive decision making in patients with chronic pain and OUD.

Eligible Conditions
  • Opioid Use Disorder
  • Chronic Pain Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~k will be calculated from the same series of discounting questions that will be asked once each session at approcimately 30 minutes after study im medication administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and k will be calculated from the same series of discounting questions that will be asked once each session at approcimately 30 minutes after study im medication administration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Delay discounting of money rate (k)
Secondary outcome measures
Peak Clinical Opiate Withdrawal Scale (COWS) Rating
Peak Increase from baseline Pupil Diameter
Peak Subjective Opiate Withdrawal Scale (SOWS) Rating
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pain GroupExperimental Treatment2 Interventions
Patients with chronic pain who are maintained on methadone for opioid use disorder
Group II: No Pain GroupPlacebo Group2 Interventions
Patients who are maintained on methadone for opioid use disorder but who do not have chronic pain.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,499 Previous Clinical Trials
11,936,459 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,253 Previous Clinical Trials
14,817,735 Total Patients Enrolled
D. Andrew Tompkins, MDPrincipal InvestigatorUniversity of California, San Francisco

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Effect of Chronic Pain on Delay Discounting in Methadone Patients
2020. "The Effect of Chronic Pain on Delay Discounting in Methadone Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04473950.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top